NEW YORK, April 9, 2019 /PRNewswire/ -- Global X ETFs,
the New York-based provider of
exchange-traded funds, announced today the launch of the
13th fund in its Thematic Growth suite, the Global X
Genomics & Biotechnology ETF (Nasdaq: GNOM). Designed to
track the Solactive Genomics Index, the fund holds a basket of
companies that potentially stand to benefit from advances in the
field of genomic science, such as companies involved in gene
editing, genomic sequencing, genetic medicine/therapy,
computational genomics, and biotechnology.
GNOM's launch comes at a time when the DNA sequencing market is
experiencing significant growth, with estimates expecting the
market to grow from $6.2 billion in
2017 to $25.5 billion by 2025 –
representing a compound annual growth rate of
19%.i As a result of significant technological
advances in the field, it's estimated that anyone with $100 can now sequence their DNA, down from the
$100 million it was estimated to cost
in 2001.ii
"The wide-ranging and transformative health benefits from
advancements in genomic technologies are astounding," said
Michael Hoffmann, research analyst
at Global X. "We're eager to see how investors engage with GNOM as
a tool for accessing this disruptive theme."
Breakthroughs in genomic science can present new treatments to
help patients recover from what were once believed to be incurable
afflictions. Scientists have identified more than 50,000 genetic
diseases caused by single-gene mutations, many of which are likely
to be treated through genomic approaches, including several methods
that have already begun to receive FDA approval.iii
ABOUT GLOBAL X
Seeking to provide access to high-quality and cost-efficient
investment solutions, Global X is a New York-based sponsor of
exchange-traded funds (ETFs). Founded in 2008, we are
distinguished by our thematic growth, income, core, international
access, commodities, alpha, and risk management suites of ETFs and
have more than 60 funds available across U.S. and foreign
exchanges. Global X is recognized as a leader in providing
intelligent investment solutions for our clients.
Investing involves risk, including the possible loss of
principal. The investable universe of companies in which GNOM may
invest may be limited. The Fund invests in securities of companies
engaged in Genomics, Healthcare and Biotechnology sectors. These
sectors can be affected by government regulations, rapid product
obsolescence, intense industry competition and loss or impairment
of patents or intellectual property rights. International
investments may involve risk of capital loss from unfavorable
fluctuation in currency values, from differences in generally
accepted accounting principles or from social, economic or
political instability in other nations. GNOM is
non-diversified.
Shares of ETFs are bought and sold at market price (not NAV) and
are not individually redeemed from the Fund. Brokerage commissions
will reduce returns.
Carefully consider the funds' investment objectives, risk
factors, charges, and expenses before investing. This and
additional information can be found in the funds' summary or full
prospectus, which may be obtained by calling 1-888-GX-FUND-1
(1.888.493.8631), or by visiting globalxfunds.com. Please read the
prospectus carefully before investing.
Global X Management Company LLC serves as an advisor to Global X
Funds. The Funds are distributed by SEI Investments Distribution
Co. (SIDCO), which is not affiliated with Global X Management
Company LLC. Global X Funds are not sponsored, endorsed, issued,
sold or promoted by Solactive AG, nor does Solactive AG make any
representations regarding the advisability of investing in the
Global X Funds. Neither SIDCO nor Global X is affiliated with
Solactive AG.
i Allied Market Research, "DNA Sequencing
Market: Opportunities and Forecasts, 2018-2025," Dec 2018.
ii Elysium Health, "The Non-Scientist's Guide to
Genetic Testing," May 22, 2018.
iii WIRED, "Gene Editing is Trickier Than
Expected—but Fixes Are in Sight," Feb 28,
2019.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/global-x-launches-gnom-an-etf-targeting-the-transformative-genomics-industry-300828035.html
SOURCE Global X Funds
